See more : Asahi Songwon Colors Limited (ASAHISONG.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Nectar Lifesciences Limited (NECLIFE.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nectar Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Metcash Limited (MTS.AX) Income Statement Analysis – Financial Results
- Forward Fashion (International) Holdings Company Limited (2528.HK) Income Statement Analysis – Financial Results
- Keck Seng Investments (Hong Kong) Limited (0184.HK) Income Statement Analysis – Financial Results
- Fingerprint Cards AB (publ) (FING-B.ST) Income Statement Analysis – Financial Results
- WM Technology, Inc. (MAPSW) Income Statement Analysis – Financial Results
Nectar Lifesciences Limited (NECLIFE.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neclife.com
About Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.84B | 15.24B | 16.69B | 15.43B | 23.66B | 27.83B | 18.76B | 16.44B | 16.76B | 16.43B | 16.38B | 16.25B | 13.03B | 10.55B | 8.86B | 7.80B | 7.74B | 4.69B | 2.91B |
| Cost of Revenue | 12.02B | 11.59B | 13.70B | 12.86B | 19.98B | 23.71B | 15.11B | 12.82B | 12.77B | 12.57B | 12.53B | 12.36B | 9.89B | 7.54B | 93.95M | -73.42M | 95.27M | -137.25M | -67.70M |
| Gross Profit | 4.82B | 3.64B | 2.99B | 2.58B | 3.69B | 4.12B | 3.65B | 3.62B | 3.98B | 3.86B | 3.85B | 3.89B | 3.14B | 3.01B | 8.76B | 7.87B | 7.65B | 4.83B | 2.97B |
| Gross Profit Ratio | 28.61% | 23.91% | 17.94% | 16.69% | 15.59% | 14.81% | 19.46% | 22.01% | 23.78% | 23.51% | 23.50% | 23.94% | 24.10% | 28.55% | 98.94% | 100.94% | 98.77% | 102.93% | 102.33% |
| Research & Development | 0.00 | 26.54M | 30.70M | 24.35M | 24.46M | 0.00 | 60.09M | 86.22M | 360.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 171.90M | 142.83M | 150.16M | 174.11M | 175.50M | 196.34M | 196.03M | 166.44M | 167.57M | 181.03M | 190.78M | 159.14M | 211.21M | 225.68M | 114.11M | 170.15M | 106.56M | 57.18M | 34.07M |
| Selling & Marketing | 389.91M | 428.67M | 480.27M | 507.87M | 463.65M | 456.59M | 287.17M | 389.99M | 343.22M | 352.53M | 247.12M | 298.36M | 188.60M | 210.75M | 224.66M | 217.57M | 161.95M | 102.15M | 72.82M |
| SG&A | 865.64M | 571.50M | 630.43M | 681.98M | 639.15M | 652.93M | 483.20M | 556.43M | 510.79M | 533.56M | 437.90M | 457.50M | 399.81M | 436.43M | 338.77M | 387.72M | 268.51M | 159.33M | 106.90M |
| Other Expenses | -20.90M | 422.39M | 112.93M | 27.22M | 9.80M | 1.46B | 1.45B | 1.44B | 1.51B | 1.42B | 1.36B | 1.29B | 985.70M | 641.50M | 6.78B | 6.40B | 6.07B | 3.92B | 2.17B |
| Operating Expenses | 932.70M | 3.70B | 1.98B | 1.95B | 2.09B | 2.11B | 1.93B | 1.99B | 2.02B | 1.96B | 1.80B | 1.75B | 1.39B | 1.08B | 7.12B | 6.78B | 6.34B | 4.08B | 2.28B |
| Cost & Expenses | 12.96B | 15.29B | 15.67B | 14.81B | 22.07B | 25.82B | 17.04B | 14.81B | 14.79B | 14.52B | 14.33B | 14.11B | 11.28B | 8.62B | 7.21B | 6.71B | 6.44B | 3.94B | 2.21B |
| Interest Income | 123.90M | 17.26M | 18.83M | 26.82M | 27.02M | 59.59M | 52.22M | 67.90M | 56.31M | 158.42M | 116.26M | 160.40M | 90.00K | 40.00K | 13.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 871.42M | 794.87M | 699.44M | 857.65M | 918.07M | 878.23M | 883.67M | 939.61M | 861.88M | 881.25M | 881.27M | 1.05B | 1.03B | 740.88M | 603.02M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 607.18M | 591.19M | 569.68M | 602.53M | 607.66M | 632.57M | 643.09M | 622.51M | 781.11M | 765.57M | 841.78M | 759.49M | 607.22M | 460.96M | 387.46M | 303.07M | 194.79M | 115.77M | 83.60M |
| EBITDA | 1.69B | 539.47M | 1.59B | 1.10B | 2.20B | 2.64B | 2.37B | 2.25B | 2.39B | 2.67B | 2.90B | 2.96B | 2.49B | 2.41B | 2.15B | 1.39B | 1.50B | 865.43M | 781.51M |
| EBITDA Ratio | 10.01% | 6.31% | 9.08% | 6.39% | 8.02% | 7.55% | 11.46% | 12.66% | 14.57% | 14.93% | 15.30% | 18.19% | 19.12% | 22.80% | 22.97% | 17.84% | 19.41% | 18.46% | 26.90% |
| Operating Income | 3.89B | -51.73M | 1.02B | 499.91M | 1.59B | 2.01B | 1.72B | 1.62B | 1.97B | 1.90B | 2.05B | 2.14B | 1.76B | 1.94B | 1.65B | 1.09B | 1.31B | 749.66M | 697.91M |
| Operating Income Ratio | 23.10% | -0.34% | 6.09% | 3.24% | 6.73% | 7.23% | 9.18% | 9.88% | 11.74% | 11.59% | 12.49% | 13.18% | 13.47% | 18.34% | 18.60% | 13.95% | 16.89% | 15.99% | 24.02% |
| Total Other Income/Expenses | -3.71B | -383.22M | -683.22M | -1.36B | -1.22B | -1.42B | -1.10B | -950.34M | -1.18B | -1.06B | -1.26B | -994.30M | -901.01M | -731.39M | -482.01M | -446.66M | -480.80M | -218.55M | -241.32M |
| Income Before Tax | 182.69M | -424.20M | 340.80M | -847.67M | 374.71M | 588.20M | 626.83M | 674.17M | 724.90M | 847.54M | 782.28M | 1.15B | 854.32M | 1.20B | 1.15B | 641.63M | 827.52M | 531.11M | 456.59M |
| Income Before Tax Ratio | 1.08% | -2.78% | 2.04% | -5.49% | 1.58% | 2.11% | 3.34% | 4.10% | 4.33% | 5.16% | 4.78% | 7.06% | 6.56% | 11.41% | 13.02% | 8.23% | 10.68% | 11.33% | 15.72% |
| Income Tax Expense | 132.74M | -182.37M | 90.34M | -115.04M | 56.82M | 112.20M | 104.11M | 120.79M | 132.96M | 184.90M | 161.43M | 290.09M | 122.16M | 173.47M | 230.10M | 111.89M | 80.13M | 63.83M | 76.70M |
| Net Income | 49.95M | -241.83M | 250.47M | -732.64M | 317.89M | 476.00M | 522.72M | 553.38M | 591.94M | 662.64M | 620.86M | 857.42M | 732.16M | 1.03B | 922.89M | 529.74M | 747.39M | 467.28M | 379.89M |
| Net Income Ratio | 0.30% | -1.59% | 1.50% | -4.75% | 1.34% | 1.71% | 2.79% | 3.37% | 3.53% | 4.03% | 3.79% | 5.28% | 5.62% | 9.77% | 10.42% | 6.79% | 9.65% | 9.97% | 13.08% |
| EPS | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 | 2.12 | 2.33 | 2.47 | 2.42 | 2.95 | 2.77 | 3.82 | 3.26 | 4.65 | 5.83 | 3.47 | 4.97 | 3.04 | 2.76 |
| EPS Diluted | 0.22 | -1.08 | 1.12 | -3.27 | 1.42 | 2.12 | 2.33 | 2.47 | 2.42 | 2.95 | 2.77 | 3.82 | 3.26 | 4.65 | 4.29 | 2.53 | 3.57 | 2.22 | 2.76 |
| Weighted Avg Shares Out | 227.05M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 159.40M | 152.26M | 149.65M | 148.87M | 137.63M |
| Weighted Avg Shares Out (Dil) | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 224.26M | 216.71M | 208.97M | 208.27M | 203.91M | 137.63M |
Source: https://incomestatements.info
Category: Stock Reports